HaiHe Biopharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel biologic drug candidates, including ADCs, for oncology.
Oncology
Technology Platform
Integrated antibody and antibody-drug conjugate (ADC) platform featuring proprietary linker and cytotoxic payload technology.
Opportunities
The ADC market is expanding rapidly, offering a major opportunity for companies with differentiated technology and novel target selection.
Risk Factors
Technical and clinical risks associated with ADC development, including toxicity management and the challenge of demonstrating superiority over existing therapies.
Competitive Landscape
Enters a fiercely competitive and rapidly evolving ADC field with major players like AstraZeneca/Daiichi Sankyo, Gilead, and numerous biotechs.